Merck subsidiary awarded $2.5bn in patent case against Gilead

Idenix Pharmaceuticals, a subsidiary of Merck, has been awarded $2.5 billion in a patent battle against Gilead over Gilead's drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), treatments for hepatitis C.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Skinny labels, big stakes: SCOTUS lines up the case of the year

21 January 2026 The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.

Americas

$5.4bn medtech leader fails to bury a rival's patent

19 January 2026 An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.

Americas

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

15 January 2026 The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.

More features

Skinny labels, big stakes: SCOTUS lines up the case of the year

Chinese biotech strikes billion dollar deal in nextgen cancer race

$5.4bn medtech leader fails to bury a rival's patent

Senior four-partner team leaves A&O Shearman

Final call: Who are the world’s best in-house counsel?

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Italian medtech startup beats larger US rival in UPC dispute

Merck subsidiary awarded $2.5bn in patent case against Gilead

More on this story

Editor's picks

Editor's picks

More features